C Difficile Infection

Potential donors are denied for a variety of reasons, including high body mass index, underlying chronic illnesses, or the use of antibiotics within 3 months.

Just 7% of patients in the BPA group suffered a recurrent CDI episode within 14-56 days of initiating treatment.

In research presented virtually at IDWeek 2021, investigators with the US Centers for Disease Control and Prevention conducted a review of nursing home antibiotic stewardship citation deficiencies in order to improve implementation.

Data from 5 trials presented at ID Week 2021 are promising for the investigational biotherapeutic.

Age, antibiotic use, and proton pump inhibitor use was associated with an increase in C difficile infections.

Healthcare provider knowledge on fecal microbiota transplantation as a treatment for inflammatory bowel disease is still lacking.

Both proton pump inhibitors and histamine 2 receptor antagonists are commonly prescribed for stress ulcer prophylaxis in critically ill patients.

RT001 and RT176 were the most prevalent C difficile ribotypes found from C difficile isolates using PCR testing.

Patients with pediatric solid tumors and hematological malignancies were more prone to C difficile infections.

FMT treatment was less effective for primary C difficile infections.

Most of Europe lacks an active and coordinated surveillance plan in place for monitoring hospital-acquired CDI.

CDI rates remained down in 2020 despite an increase in antibiotic use during the pandemic.

The new assay was 100% on both sensitivity and specificity for detecting C difficile infections from rectal swabs.

One lot of the vancomycin kits mistakenly contained a first omeprazole diluent.

Grade 3 injection site redness led to the predefined stopping rules for 10 patients in the clinical trials.

CDI patients in the RT 014-020 subgroup had better clinical outcomes.

Fluoroquinolones use within 14 days of transplantation was 1 of the strongest risk factors for C difficile infections.

Clindamycin, fluoroquinolones, and ceftriaxone are associated with the highest risk of CDI.

In the study, 5.6% of patients developed a post-operative C difficile infection.

There was not a statistically significant correlation between CDI recurrence and age, gender, previous proton pump inhibitor use, and antibiotic exposure.

There is a need for new antibiotic targets for treating C difficile infections.

Fecal microbiota transplantation could be crucial in the coming years in treating C difficile infections.

Infants between 6-12 months old had the highest prevalence of C difficile detection.

The treatment was associated with an increased risk of C difficile colitis.

This patient group was at an increased risk for future exposure to systemic corticosteroids and anti-TNF biologics.

Patients with IBD have an increased risk of developing a C difficile infection in comparison to the general population.

About 25% of IBD patients with CDI had a history of antibiotic use.

One theory as to why IBD patients are more susceptible to CDI is the use of immunosuppressant treatments.

The overall serum anti-toxin A and B antibody levels were similar at baseline between immunocompromised hosts and non-immunocompromised hosts.

Cases were identified by searching the Veterans Affairs Corporate Data Warehouse.